drugset / Trial / NCT00004229

Endostatin in Treating Patients With Advanced Solid Tumors

NCT00004229

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of endostatin in treating patients who have advanced solid tumors. Endostatin may stop the growth of cancer by stopping blood flow to the tumor.

Timeline

Start
1999-10
Primary completion
2002-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic Intravenous